Xeris Biopharma (NASDAQ:XERS) Insider Steven Pieper Sells 27,600 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 27,600 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $8.52, for a total transaction of $235,152.00. Following the completion of the sale, the insider owned 1,366,053 shares in the company, valued at approximately $11,638,771.56. The trade was a 1.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $147,900.00.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $8.94 on Wednesday. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of 149.00 and a beta of 0.62. The company’s fifty day moving average is $6.71 and its two-hundred day moving average is $6.65. Xeris Biopharma Holdings, Inc. has a 52-week low of $4.66 and a 52-week high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The business had revenue of $83.13 million during the quarter, compared to analyst estimates of $79.83 million. Equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $10.80.

Institutional Trading of Xeris Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC bought a new position in Xeris Biopharma during the fourth quarter worth about $25,000. KBC Group NV bought a new stake in shares of Xeris Biopharma in the 1st quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after purchasing an additional 7,421 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after buying an additional 5,000 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after buying an additional 1,820 shares in the last quarter. Institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.